Accelerating Drug Development is a Moral Imperative with Dr. Gabi Hanna, MD

Episode notes

For our first episode of season three, I sat down with Gabi Hanna, MD, CEO and co-founder of Lamassu Biotech, where he leads the development of innovative therapies for cancer and inflammatory diseases. A physician-scientist and serial entrepreneur, Dr. Hanna previously founded the first academic drug development center at Duke University and has authored over 50 peer-reviewed publications. Under his leadership, Lamassu is advancing two novel therapeutics - RABI-767, now in Phase II trial, and SA53, a first-in-class oncology compound currently in Phase I/II trial. He also oversees Lamassu Pets, which is developing a canine therapy for pancreatitis. Dr. Hanna’s work is driven by a commitment to rapid, cost-effective drug development that addresses unmet clinical needs. We discuss the mission of Lamassu Biotech, as well as the importance of academic accelerator programs, overcoming regulatory roadblocks, and the moral duty to accelerate drug development for patient care. Gabi emphasizes the need for efficient operations, strategic partnerships, and a patient-centric approach in biotech.

• Putting the “Tech” in Biotech: An Unconventional Path to Building a Therapeutics Company, with Federico Paoletti, PhD72 / 100
• Biotech, Blockchain, and Building Companies with Russ Peloquin, Managing Partner of LifeSci Catalyst Partners
• Funding, Partnerships, and Growth: Strategies for Startup Biotech Success with Fractional Chief Business Officer Renee Williams
• Trust, Teamwork, and Innovation, with Natalie Nairn, Co-founder and CEO of Cyclera Therapeutics
• The Science of Success: Transforming Scientific Concepts into Marketable Products with Stacy Frye, co-founder and CCO of Stimulus Bio